Articles
Pharmacovigilance
In-depth, citation-backed writing on pharmacovigilance. · 2 articles in Pharmacovigilance
What Safety Signals Has MK-677 (Ibutamoren) Produced in Human Trials, and How Serious Is the Congestive Heart Failure Risk in 2026?
Ibutamoren mesylate has produced clinically significant safety signals in human trials. The most serious is congestive heart failure and a trial was terminated early after CHF occurred in six-point-five percent of treated elderly patients versus one-point-six percent on placebo. Ibutamoren carries no FDA approval as of 2026.
Do GLP-1 Receptor Agonists Increase the Risk of Clinically Recorded Hair Loss Compared With Other Diabetes Drug Classes in 2026?
A 2024 BMJ target-trial emulation using Penn Medicine electronic health records found that GLP-1 receptor agonist initiators had a statistically significant higher incidence of clinically recorded alopecia than users of DPP-4 inhibitors or SGLT-2 inhibitors, with an adjusted hazard ratio of approximately 1.33 versus DPP-4 inhibitors after propensity-score weighting.